Search clinical trials for: Placebo-matching Ubrogepant

Total 54204 results

Allergan

Completed

Efficacy, Safety, and Tolerability of Oral Ubrogepant in the Acute Treatment of Migraine (ACHIEVE II)

Migraine, With or Without Aura

United States
Allergan

Completed

Efficacy, Safety, and Tolerability Study of Oral Ubrogepant in the Acute Treatment of Migraine (ACHIEVE I)

Migraine, With or Without Aura

United States
AbbVie

Recruiting

Study to Assess Adverse Events and Disease Activity of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Children and Adolescents (Ages 6-17)

Migraine

United States, Puerto Rico
Allergan

Completed

An Extension Study to Evaluate the Long-Term Safety and Tolerability of Ubrogepant in the Treatment of Migraine

Migraine, With or Without Aura

United States
AbbVie

Completed

Study to Evaluate Oral Ubrogepant in the Acute Treatment of Migraine During the Prodrome in Adult Participants (UBR Prodrome)

Migraine

United States
Chicago Headache Center & Research Institute
AbbVie

Recruiting

Ubrogepant treatmeNt in mIgraine Patients Utilizing mOnoclonal aNtibodies (UNION)

Headache, Migraine

United States
AbbVie

Enrolling by invitation

Long-term Extension Study to Assess Safety and Tolerability of Oral Ubrogepant Tablets for the Acute Treatment of Migraine in Pediatric Participants (Ages 6-17)

Migraine

United States, Puerto Rico
AbbVie

Completed

Study To Assess Adverse Events and Drug to Drug Interaction of Oral Tablet Atogepant and Ubrogepant in Adult Participants With a History of Migraine

Migraine

United States
AbbVie

Completed

Study to Assess Adverse Events and Compare How Oral Ubrogepant and Oral Atogepant Moves Through the Body of Healthy Female Adult Volunteers

Healthy Volunteers

United States
AbbVie

Completed

Study to Assess Adverse Events When Ubrogepant Tablets in Combination With Atogepant Tablets Are Used to Treat Adult Participants With Migraine (TANDEM)

Episodic Migraine

United States
Nowarta Biopharma Inc

Completed

A Phase I/II Double-blind Safety and Efficacy Evaluation of Nowarta110 in Patients With Plantar Warts

Plantar Warts

United States
China Medical University Hospital

Completed

Bath Machine on Sleep Quality in Nursing Home

Sleep

Taiwan
Resverlogix Corp

Not yet recruiting

A Two-Part Phase 2a Study of RVX000222 in Patients With End-Stage Renal Disease Treated With Hemodialysis

Kidney Failure, Chronic
Syneos Health
Shanghai Novamab Biopharmaceuticals Co. Ltd.

Terminated

First-In-Human Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacokinetics of LQ036

Asthma

Australia
Huabo Biopharm Co., Ltd.

Completed

A Study of HB0017 in Patients With Moderate to Severe Plaque Psoriasis

Plaque Psoriasis

China
GlaxoSmithKline

Recruiting

Efficacy and Safety of Depemokimab Compared With Mepolizumab in Adults With Relapsing or Refractory Eosinophilic Granulomatosis With Polyangiitis (EGPA) (OCEAN)

Eosinophilic Granulomatosis With Polyangiitis

Canada, France, Italy, Spain, Belgium, Korea, Republic of, United States, Japan, China, Czechia, Hungary, Israel, Portugal, Poland, Netherlands, United Kingdom, Austria, Argentina, Australia, Brazil, Germany, Sweden
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

DBPR108 Tablets in Type 2 Diabetes Mellitus Patients

Type 2 Diabetes Mellitus

China
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Completed

Tolerability and Pharmacokinetics of CSPCHA115 Capsules in Chinese Healthy Volunteers

Asthma; Allergic Rhinitis

China
Anji Pharma
Covance

Completed

A Proof of Concept Study of Pradigastat in Patients With Functional Constipation

Functional Constipation

China, United States
YSOPIA Bioscience

Completed

Xla1 Christensenella Minuta, Phase I, Randomized, Partially Placebo-controlled Double-blind Protocol, Evaluating Safety, Tolerability and Impact on the Gut Microbiota in Healthy Volunteers, Overweight and Obese Adults (CAUSALITY)

Obesity | Metabolic Disease

United States
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.

Unknown

Phase I Study of Direct Coagulation Factor Xa Inhibitor SYHA136 Tablets in Chinese Healthy Volunteers

Venous Thrombosis
Immune Design

Terminated

A Phase 3, Randomized, Double-blind, Placebo-controlled Study For Subjects With Locally-advanced Unresectable or Metastatic Synovial Sarcoma (V943-003, IMDZ-04-1702)

Sarcoma | Soft Tissue Sarcoma | Cancer | Synovial Sarcoma | Metastatic Sarcoma

United States, Canada
Johnson & Johnson Pharmaceutical Research & Development...

Completed

Single and Multiple Dose Study to Explore the Safety and Pharmacokinetics of JNJ-39758979 In Healthy Male Volunteers of Either Caucasian or Japanese Descent

Healthy

United States
Intercept Pharmaceuticals

Not yet recruiting

Study to Assess Efficacy, Safety, Tolerability, Pharmacokinetics (PK), and Pharmacodynamics (PD) of Obeticholic Acid (OCA) Compared to Placebo in Pediatric Participants With Biliary Atresia, Post-hepatoportoenterostomy

Biliary Atresia
New Beta Innovation Limited

Terminated

YQ23 Study in Patients With Critical Limb Ischaemia (YAN)

Critical Limb Ischemia

Hong Kong
SIMR (Australia) Biotech Pty Ltd.

Completed

A Phase 1 Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of SR1375

Healthy Volunteers

Australia
Bayer

Completed

A Study to Learn More About the Safety and the Level of BAY 1747846 in Body Given as Injection Into the Vein at Increasing Single Doses in Japanese Healthy Male Participants

Healthy Volunteers | Contrast Enhancement in Magnetic Resonance Imaging

Japan
Bayer

Completed

Repeat Doses of BAY 1817080 in Healthy Males & Proof of Concept in Chronic Cough Patients

Cough

United Kingdom
Astellas Pharma Global Development, Inc.

Completed

A Study to Assess Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ASP4345 in Patients With Schizophrenia

Schizophrenia

United States
Kyowa Hakko Kirin Pharma, Inc.

Completed

A Study of Single and Multiple Doses of KHK6640 in Subjects With Prodromal or Mild to Moderate Alzheimer's Disease

Alzheimer's Disease

Belgium, Finland, Netherlands, Serbia, Sweden
Merck Sharp & Dohme LLC

Terminated

Study Assessing Single and Multiple Doses of IDX21459 in Healthy and HCV-Infected Subjects

Chronic Hepatitis C
Celldex Therapeutics

Recruiting

A Study of Barzolvolimab in Patients With Prurigo Nodularis

Prurigo Nodularis

United States
Merit E. Cudkowicz, MD
Ra Pharmaceuticals

Completed

HEALEY ALS Platform Trial - Regimen A Zilucoplan

Amyotrophic Lateral Sclerosis

United States
Merit E. Cudkowicz, MD
Biohaven Pharmaceuticals, Inc.

Completed

HEALEY ALS Platform Trial - Regimen B Verdiperstat

Amyotrophic Lateral Sclerosis

United States
New Beta Innovation Limited

Completed

First-In-Man, Healthy Volunteer Study to Evaluate Safety on the Use of YQ23

Healthy Volunteers

United Kingdom
Novartis Pharmaceuticals

Terminated

Safety, Pharmacokinetics and Efficacy Study of QCC374 in PAH Patients

Pulmonary Arterial Hypertension

Germany, Korea, Republic of, United Kingdom, United States
Beech Tree Labs, Inc.
Norwich Clinical Research Associates Ltd.

Completed

Safety and Efficacy Study of a New Treatment for Symptoms of Urinary Incontinence

Urinary Incontinence

United States
Celldex Therapeutics

Recruiting

A Study of CDX-0159 in Patients With Eosinophilic Esophagitis (EvolvE)

Eosinophilic Esophagitis

United States, Spain, United Kingdom, Canada, Italy, Poland, Australia, Germany
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety, Tolerability, Pharmacodynamics and Pharmacokinetics of NIO752 in Early Alzheimer's Disease Participants

Alzheimer Disease | Mild Cognitive Impairment

France, Spain, Sweden, Finland
Jiangsu HengRui Medicine Co., Ltd.

Withdrawn

A Clinical Study of Hetrombopag Olamine Tablets in Adults Receiving 21-day Cycles of Chemotherapy for Solid Tumours, Who Are Delayed for at Least 1 Week From Their Scheduled Cycle Because of Chemotherapy-induced Thrombocytopenia

Chemotherapy-Induced Thrombocytopenia
Bayer

Completed

Study on the Safety of Drug BAY1817080 at Different Doses and the Way the Body Absorbs and Eliminates the Drug in Japanese Healthy Adult Male Participants

Overactive Bladder | Diabetic Neuropathic Pain | Endometriosis Related Pain | Refractory or Unexplained Chronic Cough

Japan
Regeneron Pharmaceuticals

Completed

A Study to Examine the Safety, Tolerability and Effects on Abnormal Bone Formation of REGN2477 in Patients With Fibrodysplasia Ossificans Progressiva (LUMINA-1)

Fibrodysplasia Ossificans Progressiva

United States, Spain, Canada, France, Poland, Italy, Netherlands, United Kingdom
Regeneron Pharmaceuticals

Terminated

A Study to Examine the Efficacy and Safety of REGN5069 in Patients With Pain Due to Osteoarthritis of the Knee

Pain | Osteoarthritis of the Knee

United States, Georgia, Moldova, Republic of, Poland, Ukraine
Genentech, Inc.

Completed

A Study to Investigate the Safety, Tolerability, and Pharmacokinetics of MHAB5553A in Healthy Volunteers

Healthy Volunteer

Canada
AstraZeneca
Parexel

Terminated

A Phase I Study to Assess the Safety, Tolerability, Pharmacokinetics, Pharmacodynamics and Food Effect of AZD9898

Asthma

United Kingdom
Hoffmann-La Roche

Terminated

A Study to Investigate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RO7020322 Following Oral Administration in Healthy Participants and Chronic Hepatitis B Patients

Hepatitis B, Chronic

Hong Kong, Taiwan, New Zealand
Icahn School of Medicine at Mount Sinai
Sanofi; Regeneron Pharmaceuticals; Rockefeller University

Completed

Treatment of Alopecia Areata (AA) With Dupilumab in Patients With and Without Atopic Dermatitis (AD)

Alopecia Areata

United States
Annexon, Inc.
Nucleus Network Ltd

Completed

A Single and Multiple Ascending Dose Study of ANX009 in Normal Healthy Volunteers (NHV)

Safety and Tolerability in Healthy Volunteers

Australia
PTC Therapeutics

Completed

Long-Term Outcomes of Ataluren in Duchenne Muscular Dystrophy

Nervous System Diseases | Genetic Diseases, Inborn | Genetic Diseases, X-Linked | Muscular Diseases | Neuromuscular Diseases | Muscular Dystrophies | Muscular Disorders, Atrophic | Muscular Dystrophy, Duchenne | Musculoskeletal Disease

United States, Taiwan, India, Korea, Republic of, Thailand, Australia, Brazil, Bulgaria, Canada, China, Hong Kong, Malaysia, Mexico, Poland, Puerto Rico, Russian Federation, Turkey, Japan
Syneos Health
Otsuka Pharmaceutical Development & Commercialization, Inc.

Terminated

To Assess the Safety, Tolerability and Pharmacokinetics of ACH-000029 in Healthy Subjects

Healthy Volunteers

Australia

3

Subscribe